Health & Biotech
Pacific Equity Partners Makes Bid for Healthia
In the constantly evolving healthcare sector, significant movements can reshape the industry’s trajectory. Healthia, a notable entity in the allied healthcare landscape, stands at the
InhaleRx Advances CBD Drug Clinical Trials
Australian healthcare company InhaleRx (ASX: IRX) has achieved significant advancements in its clinical trials involving cannabinoid (CBD)-derived drugs. The company has taken meaningful steps forward
BCAL Diagnostics Advances Commercialisation
Australian biotechnology firm BCAL Diagnostics (ASX: BDX) has achieved a significant breakthrough in its mission to revolutionize breast cancer screening. The company has unveiled a
Rivalry intensifies as pathology companies argue over details
Australian Clinical Labs and Healius, the second and third largest players in Australia’s pathology sector, are considering a merger, which could result in a new
Imugene progresses phase one trial of cancer-fighting virus
Imugene (ASX: IMU), a clinical stage immune-oncology company, has commenced the dosing of a third cohort of patients in a monotherapy dose escalation trial for
Artificial Intelligence’s Emergence in Healthcare
Artificial intelligence (AI) is making huge strides in the healthcare sector, where access to vast amounts of data allows the technology to develop and practice.
Australia’s first biotech incubator kicks off with $40m grant
The Medical Research Commercialisation Fund (MRCF) will establish a national biotech incubator in Australia following a AUD 40m ($31m) grant from the government’s Medical Research
Australia’s biotechnology industry focused on innovation at its core
The COVID-19 pandemic has highlighted the importance of the life sciences sector, which was already a significant industry in Australia. In 2021, the sector experienced
Australia an Emerging Bio Tech Super Player
Australia has a strong base in biotechnology with many incentives for R&D and commercialization, including tax offsets for R&D activities and sources of capital like
Andrew Forrest invests $250m in Tenmile to accelerate development of life-changing health technology
Australian mining magnate Andrew Forrest has invested AUD 250m ($190m) in Tenmile, a new biotech venture capital group, through his private investment firm Tattarang. Tenmile
Cancer Biotech Start-Up Receives $10 Million Funding with Backing from Brandon Capital and Uniseed
Melbourne-based start-up Currus Biologics has raised $10m to develop its cancer immunotherapy, which targets solid tumours such as breast and pancreatic cancers. The Medical Research
Biotech investors – Do they need a research ombudsman?
Investors in the digital health and biotech industries in Australia are not adequately informed about the quality of research being produced by local health sciences
CAR-T Therapy – The next medical revolution?
CAR-T (Chimeric Antigen Receptor T-cell) therapy has been hailed as a groundbreaking approach to cancer treatment, but it has not yet become mainstream since the
CSL – The Next Market Darling?
Melbourne-based biotech company, CSL, has become one of the world’s most valuable biotech companies, now ranking third in the world, behind only US-based Amgen and
Shareholder of Australian Clinical Labs approves Healius takeover plan and boosts stake
Ethical Partners, a boutique fund manager and third-largest shareholder of Australian Clinical Labs (ACL), has increased its stake in the diagnostic testing company to 8.7%
Labor considering abandoning tax incentive for medical patents
The Australian Labor government has decided to scrap the “patent box” tax break designed for the medical and biotech industry by the former Coalition government.
Establishing a Benchmark Approach for the Translation of Health and Medical Research
Australian universities could be at the global forefront of research translation and commercialisation in health and medicine if barriers to collaboration are overcome and best
Melbourne – At the Forefront of Australia’s Medical Research and Biotechnology Industry
Victorian Acting Premier James Merlino has announced that Melbourne is among the top three leading cities in medical research and biotechnology. The state has secured
How do biotech stocks perform during market downturns?
Investors are increasingly sceptical of biotech stocks, which have been down on the Nasdaq 12.38% over the past year, and many regard the sector as
PharmAla Biotech Enters Sales Agreement to Supply Clinical-Grade MDMA in Australia
PharmAla Biotech Holdings Inc., the only manufacturer and exporter of clinical-grade MDMA in the world, has signed a sales agreement with Australian drug developer Emyria
National biotech incubator supports Monash University’s innovative projects with $2.5M funding
Monash University-led biotech projects have been awarded AUD 2.5 million ($1.8 million) by the Australian biotechnology incubator CUREator to advance novel therapeutics and preclinical medical
Vida Ventures Managing Director Optimistic about Long-Term Biotech Investment in Australia
The Covid-19 pandemic highlighted Australia’s biotechnology sector, as companies worked to develop vaccines and treatments for the virus. AusBiotech has seen a 40% growth in
Need for increased funding to bring Australia’s biotech innovations to market and prevent offshore relocation
The COVID-19 pandemic has highlighted the importance of the healthcare sector, and Australian researchers are making strides in the field of biotech. Scientists have developed
Clinical Labs attempts ambitious merger with Healius in a strategic move
Australian Clinical Labs (ACL), a private equity-backed pathology company, has made an all-scrip offer to acquire Healius, the No.2 player in the market, via a
First Patients Dosed in Combination Trial as Imugene Advances Development of Novel Cancer-Killing Virus
Imugene, an Australian immuno-oncology company, has begun dosing patients in a combination study evaluating its novel cancer-killing virus, CF33 oncolytic virotherapy, in metastatic advanced solid
Imugene Secures US Patent for PD1-Vaxx
Imugene (IMU), a specialist in immuno-oncology, has recently been granted a patent by the US Patent and Trademark Office (USPTO) for its PD1-Vaxx lung cancer